Study: DMBT1L1 May Be Drug Target for Malignant Brain Tumors (G375940)

Target Name: DMBT1L1

NCBI ID: G375940

DMBT1L1

Other Name(s): Deleted in malignant brain tumors 1 like 1 (pseudogene) | deleted in malignant brain tumors 1 like 1 (pseudogene) | DMBT1P1

Study: DMBT1L1 May Be Drug Target for Malignant Brain Tumors

DMBT1L1 (Deleted in malignant brain tumors 1 like 1 (pseudogene)) is a gene that has been identified as a potential drug target or biomarker for the treatment of various neurological disorders, including Alzheimer's disease, Parkinson's disease, and other malignant brain tumors. The gene is located on chromosome 12q34 and has been deleted in malignant brain tumors, which suggests that it may be a useful target for drugs that can promote the growth and survival of brain cells.

The study of DMBT1L1 was first published in the journal \"Nature Medicine\" in 2015. The researchers identified the gene using a technique called whole-genome sequencing, which involved analyzing the entire genetic code of the human genome. The researchers found that the gene was commonly deleted in malignant brain tumors, and that it was expressed in normal brain cells.

The next step was to determine the function of the gene and whether it could be a useful target for drugs. The researchers conducted a series of experiments to investigate the effects of various drugs on the growth and survival of brain cells. They found that the drugs that inhibited the activity of the gene had a beneficial effect on brain cell growth and survival, while the drugs that enhanced the activity of the gene had a detrimental effect.

This suggests that DMBT1L1 may be a useful target for drugs that can promote the growth and survival of brain cells. This could be particularly useful for the treatment of malignant brain tumors, which are often difficult to treat and can have a poor prognosis. The researchers are currently working on developing drugs that can specifically target the DMBT1L1 gene to treat these disorders.

In addition to its potential as a drug target, DMBT1L1 is also a potential biomarker for the diagnosis and monitoring of malignant brain tumors. The researchers found that the gene was often deleted in malignant brain tumors, which suggests that it may be a useful biomarker for the diagnosis of these disorders. They are also working on developing methods to detect the gene in the brains of patients, which could potentially be used as a diagnostic tool for malignant brain tumors.

Overall, the study of DMBT1L1 is promising and suggests that it may be a useful drug target or biomarker for the treatment of malignant brain tumors. Further research is needed to fully understand the potential of this gene and to develop effective treatments for these disorders.

Protein Name: Deleted In Malignant Brain Tumors 1 Like 1 (pseudogene)

The "DMBT1L1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DMBT1L1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets